Nasopharyngeal  S. pneumoniae  carriage and density in Belgian infants after 9 years of pneumococcal conjugate vaccine programme by Wouters, Ine et al.
Vaccine 36 (2018) 15–22Contents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vacc ineNasopharyngeal S. pneumoniae carriage and density in Belgian infants
after 9 years of pneumococcal conjugate vaccine programmehttps://doi.org/10.1016/j.vaccine.2017.11.052
0264-410X/ 2017 The Author(s). Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations: AOM, acute otitis media; CRO, clinical research organisation; Chi2, Chi-Square test; DCC, day-care centre; GP, general practitioner; IPD,
pneumococcal disease; MWU, Mann-Whitney U test; NP, nasopharyngeal; PCV, pneumococcal conjugate vaccine; STGG, skim milk-tryptone-glucose-glycerol.
⇑ Corresponding author at: University of Antwerp, Campus Drie Eiken, Building R – 2nd floor, Belgium.
E-mail address: ine.wouters@uantwerpen.be (I. Wouters).
1 NPcarriage Study Group: Marc Verghote, private practice, Namur, Belgium; Jean-Philippe Stalens, Centre Hospitalier de Wallonie Picarde, campus UNION, Tournai,
Marc De Meulemeester, private practice, Gozée, Belgium; Robert Cohen, Université Paris Est, IMRB-GRC GEMINI, 94000 Créteil, France; Adam Finn, University of Bristol,
Cellular and Molecular Medicine, Bristol, UK; Koen Van Herck, Department of Public Health, Ghent University, Ghent, Belgium, Centre for the Evaluation of Vaccination
and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium; David Tuerlinckx, CHU Dinant-Godinne, Université Catholique de Louvain, Yvoir, Belgium.Ine Wouters a,⇑, Liesbet Van Heirstraeten b, Stefanie Desmet c, Stéphanie Blaizot d, Jan Verhaegen c,
Herman Goossens b, Pierre Van Damme a, Surbhi Malhotra-Kumar b, Heidi Theeten a, NPcarriage Study
Group 1
aCentre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, 2610 Wilrijk, Belgium
b Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, 2610 Wilrijk, Belgium
cReference Centre for Pneumococci, University Hospitals Leuven, Campus Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
dCentre for Health Economics Research and Modelling Infectious Diseases, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, 2610 Wilrijk, Belgium
a r t i c l e i n f o a b s t r a c tArticle history:
Received 24 August 2017
Received in revised form 6 November 2017
Accepted 15 November 2017






InfantsBackground: In Belgium, the infant pneumococcal conjugate vaccine (PCV) programme changed from
PCV7 (2007–2011) to PCV13 (2011–2015) and to PCV10 (2015–2016). A 3-year nasopharyngeal carriage
study was initiated during the programme switch in 2016. Main objective of the year 1 assessment was to
obtain a baseline measurement of pneumococcal carriage prevalence, carriage density, serotype distribu-
tion and antibiotic resistance.
Materials/methods: Two infant populations aged 6–30 months and without use of antibiotics in the seven
days prior to sampling were approached: (1) attending one of 85 randomly selected day-care centres
(DCC); (2) presenting with AOM at study-trained general practitioners and paediatricians.
Demographic and clinical characteristics were documented and a single nasopharyngeal swab was taken.
S. pneumoniae were cultured, screened for antibiotic resistance and serotyped, and quantitative Taqman
real-time PCR (qRT-PCR) targeting LytA was performed.
Results: Culture-based (DCC: 462/760; 60.8% – AOM: 27/39; 69.2%) and LytA-based (DCC: 603/753; 80.1%
– AOM: 32/39; 82.1%) carriage prevalence was high. Average pneumococcal DNA load in LytA-positive
day-care samples was 6.5  106 copies/ml (95%CI = 3.9–9.2  106, median = 3.5  105); DNA load was
positively associated with signs of common cold and negatively with previous antibiotic use. Culture-
based frequency of 13 pneumococcal vaccine (PCV) serotypes was 5.4% in DCC and 7.7% in AOM, with
19F and 14 being most frequent, and frequencies below 0.5% for serotypes 3, 6A, 19A in both populations.
Predominant non-PCV serotypes were 23B and 23A in day-care and 11A in infants with AOM. In day-care,
resistance to penicillin was rare (<0.5%) and absent against levofloxacin; 32.7% and 16.9% isolates were
cotrimoxazole- and erythromycin-resistant respectively.
Conclusion: Four years after PCV13 introduction in the vaccination programme, PCV13 serotype carriage
was rare in infants throughout Belgium and penicillin resistance was rare. Continued surveillance in the
context of a PCV programme switch is necessary.
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More than 90 S. pneumoniae serotypes exist and reside in the
human upper respiratory tract [1]. Pneumococcal carriage is a
highly dynamic process with subsequent episodes of acquisition,
carriage and clearance [2]. Reported asymptomatic carriage is
between 30% and 62% in infants under two years of age in Western
countries [3]. Higher carriage rates (up to 93% in Gambian babies <
1 month) were reported in non-Western countries [4]. In circum-
stances such as host-pathogen imbalance, pneumococci may
spread and reach respiratory organs or even the bloodstream to
cause infections, including otitis media, pneumonia, sepsis and
meningitis [3,5,6].
Infants under two years of age constitute the major reservoir
and source of transmission [7]. Furthermore, they are at high risk
of pneumococcal disease of which the most common is acute otitis
media (AOM) [2]. Therefore, this age group is an interesting popu-
lation to be studied for nasopharyngeal (NP) carriage.
Pneumococcal disease risk increases if infants reside in day-care
centres (DCC), a setting associated with enhanced pneumococcal
carriage and antimicrobial resistance [8,9]. Also, the crowded
DCC environment facilitates transmission from one infant to
another.
With an overall incidence of 299/1000 person-years in infants
up to two years of age as reported from five European countries
[10], AOM is the major reason for paediatric consultation and
antibiotic prescription [11,12]. Worldwide, S. pneumoniae causes
28–55% of AOM episodes, making it the dominant bacterial patho-
gen implicated in the development of AOM [13–16]. The extensive
prescription and use of antibiotics promotes antimicrobial resis-
tance, compromising the ability to effectively treat pneumococcal
infection and emphasising the importance of preventing pneumo-
coccal disease via vaccines [17].
In Belgium, a PCV7 programme with free of charge vaccine was
started in 2007 (2+1 schedule). It quickly reached high 3-dose cov-
erage in infants: from 89.1% in 2008 to 96.5% in 2012 in Flanders
(Northern part of Belgium) and from 80.7% in 2009 to 89.2% in
2012 in Wallonia (Southern part of Belgium) [18–21]. Four years
later, PCV13 was introduced and recently replaced by PCV10, with
regional difference in timing: (1) Flemish infants were PCV13 vac-
cinated up to the end of June 2015 and thereafter received PCV10
for their further schedule; (2) Walloon infants were PCV13 vacci-
nated until the end of April 2016 and thereafter received PCV10;
(3) In Brussels-Capital-Region, the individual vaccine offer
depended on the particular general practitioner (GP) or paediatri-
cian consulted (Flemish or Walloon programme). This change in
the Belgian universal vaccination programme was an outcome of
the regular tender processes for all vaccines (after expiry of a
previous contract), during which the Belgian regions decide
autonomously, based on different vaccine characteristics, including
price [22].
The introduction of PCV10, lacking PCV13 serotypes 3, 6A, 19A,
in European countries such as Austria and Finland resulted in a
decreased incidence of invasive pneumococcal disease (IPD), but
with a high proportion (70–86% in children) of PCV13-
preventable cases among remaining invasive IPD, dominated by
serotypes 19A and 3 [23–26]. Although case-control studies in sev-
eral countries have shown early effectiveness of PCV10 against
19A-IPD, continued surveillance data suggest waning of this
cross-protection [27]. In Belgium (up to 2016), remaining IPD in
infants after PCV13 introduction was dominated by non-PCV13
serotypes [28].
Pneumococcal conjugate vaccines (PCV) do not only generate
direct protection, but also reduce carriage of pneumococcal sero-
types present in the vaccine. Such indirect effects of PCV vaccinationin infants have been suggested to protect older age groups too and
several IPD-surveillance data from other countries are supportive,
but the effect size varies and is being downgraded through replace-
ment by non-vaccine serotypes causing IPD [29–31]. Carriage data
are essential to understand pneumococcal biology and transmission
and to anticipate changes in IPD. The unique Belgian situation of a
PCV programme that altered from PCV7 to PCV13 and then to
PCV10and reachedhigh coverage in infants, created theopportunity
for an observational follow-up study onNP carriage of S. pneumoniae
in infants. The baseline results of this three-year carriage study
which started in 2016 are presented here. Specific objectives were:
to obtain a baseline measurement of pneumococcal carriage preva-
lence, carriage density, serotype distribution and antibiotic resis-
tance; to compare pneumococcal carriage between regions and
between infants with AOM and healthy infants in day-care; and to
identify other predictors of carriage and density.2. Materials and methods
The current cross-sectional study investigates carriage in two
infant populations with high reported carriage of S. pneumoniae:
those attending DCC and those with AOM. The protocol of the
AOM part was based on that of a similar 13-year survey by Cohen
et al. [32]. Since pneumococcal carriage and AOM incidence are
both lower in summer, recruitment is restricted to non-summer
seasons (October to June) from 2016 to 2018 at least. The first sam-
pling period was between January and June 2016, i.e. during and
shortly after the switch in vaccination programme (Fig. 1). Protocol
details are added in the Supplement and summarised here.2.1. Study population
After ethics approval of the study, recruitment started in: (1)
healthy infants residing in one of 85 DCC randomly selected over
the three Belgian regions and (2) infants with AOM visiting one
of 55 trained GP’s or paediatric outpatient services (private or hos-
pital) throughout Belgium.
Age limits for inclusion were 6 months (to limit inclusion of
unvaccinated infants) and 30 months and for the baseline assess-
ment in the first recruitment season, region-specific age criteria
were added to include only infants who were offered PCV13 for
both primary vaccine doses in the first year of life.
AOM was defined by the acute onset (i.e. within the preceding
seven days) of symptoms and specified otoscopic criteria.
Exclusion criteria were: (1) second inclusion in the same winter
season, (2) use of oral antibiotics in the past seven days, (3) pres-
ence of a chronic and severe pathology.2.2. Nasopharyngeal samples and questionnaire
After parents gave written informed consent, a trained nurse or
a GP/paediatrician collected a single NP swab and a parent ques-
tionnaire about demographic and clinical characteristics and pneu-
mococcal vaccination status. Signs of common cold were defined as
coughing and/or running nose.2.3. Cultures – Serotyping – Antibiotic susceptibility
At the Reference Centre for Pneumococci at the University
Hospitals in Leuven, NP samples were cultured, S. pneumoniae
strains were serotyped and antibiotic susceptibility to penicillin,
tetracycline, erythromycin, levofloxacin and cotrimoxazole was
determined following CLSI 2016 guidelines [33].
Fig. 1. Study flow: chronological representation of changes in pneumococcal conjugate vaccine (PCV) programme in Belgium (upper part) and planned data collection periods
(lower part).
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Concentrations of pneumococcal DNA were determined using
quantitative Taqman real-time PCR (qRT-PCR) targeting LytA [34].
Bacterial densities were determined based on a standard curve that
was set up using 10-fold serially diluted LytA PCR product of S.
pneumoniae strain ATCC 49619 [35]. Samples and standard curves
were run in triplicate.
2.5. Statistical analysis
The current baseline assessment presents the Walloon, Brussels
and Flemish cohorts. The results of Brussels infants are shown in
order to present complete results, but they were not separately
taken into account for comparative analyses.
The Chi-Square test (Chi2) and the Mann-Whitney U test
(MWU) were used to test significance at a level of 5%. 95% confi-
dence intervals on proportions were calculated with continuity
correction. Missing values were not replaced.
3. Results
3.1. Recruitment and infant characteristics
A total of 856 NP samples were collected of which 760 per pro-
tocol DCC samples and 39 per protocol AOM samples were included
in the statistical analyses. The 57 remaining samples were
excluded due to inappropriate age or antibiotic treatment in the
seven days prior to sampling. Because of the low number of infants
with AOM, less detailed results are given for AOM than for DCC
infants (Table 1).
3.2. Quality check of sampling procedure
3.2.1. Sampling depth
The majority of the samples (73.0% for DCC, 38/39 for AOM) was
taken at a depth of at least half the distance between the nostril
and the ear lobe and only 3.0% of the DCC samples and one AOM
sample were taken at a depth of less than 1 cm from the nostril.
In DCC infants, carriage prevalence and carriage density were not
statistically different between samples taken at more or less than
half the distance between nostril and ear lobe, excluding <1 cm.
3.2.2. Freeze-thaw cycle prior to culture
AOM samples were immediately cultured upon arrival, whereas
the majority of DCC samples (85.3%, n = 112) was frozen at 80 C
prior to culture and within 12 h after sampling. Detection rate of S.
pneumoniae was similar in frozen (60.3%) and in non-frozen DCCsamples (63.3%) (Chi2, P = .541). Pneumococcal loads were also
similar among frozen (7.6  106 copies/ml, 95%CI = 4.2–10.9  106,
median = 0.5  106) and non-frozen (1.0  106 copies/ml 95%CI = 0
.6–1.4  106, median = 0.4  106) samples.3.3. Main findings
3.3.1. Carriage prevalence
Culture-based carriage prevalence was similar in DCC (60.8%)
and in AOM (69.2%). For infants in day-care, LytA-based carriage
prevalence was 80.1% and similar in Wallonia (78.3%) and in Flan-
ders (83.2%). LytA-based carriage prevalence in infants with AOM
was 82.1%. Two characteristics were negatively associated with
carriage in DCC infants: parental smoking with culture-positivity
of the sample and antibiotic use in the three months prior to sam-
pling with LytA-positivity of the sample (Table 2). Antibiotic use
was not associated with culture-negativity of LytA-positive sam-
ples (Chi2, P > .1).3.3.2. Carriage density
Average pneumococcal DNA load in LytA-positive samples of
infants in day-care was 6.5  106 copies/ml (95%CI = 3.9–9.2  10
6, median = 3.5  105), similar among culture-positive (6.6  106
copies/ml) and culture-negative (6.3  106 copies/ml) samples and
seven times higher in DCC infants than in AOM infants (0.9  106
copies/ml, 95%CI = 0.31–1.5  106, median = 0.2  106) (MWU, P =
.042).
In infants in day-care, significantly higher pneumococcal loads
were found when signs of common cold (27.8%) were present at
sampling (Table 3). In contrast, antibiotic use in the previous three
months was associated with lower pneumococcal loads. PCV13
serotype carriage was not related to carriage density in DCC
infants.3.3.3. Serotype distribution
Among culture-positive samples, frequency of PCV13 serotypes
was low. Serotype 19F was most frequent (half of the cases in DCC
and in AOM), followed by serotype 14 (16.0% of DCC cases, half of
AOM cases, only identified inWallonia) and in DCC by 23F and 19A.
PCV13 serotype carriage was similar in Wallonia and in Flanders
for each setting. Among the unvaccinated DCC infants (4.4%, n =
33), one 19F was detected, resulting in a PCV13 serotype frequency
(4.5%) similar to the vaccinated population. For non-PCV13 sero-
types, 23B and 23A were predominant in DCC and 11A and 23B
in AOM. Regarding the PCV13 non-PCV10 serotypes (3, 6A, 19A),
extremely low frequencies were detected (0.9%; 95%CI = 0.3–2.4%
in DCC) (Table 4).
Table 1
Basic characteristics of participating infants per setting and per region, 2016.
DCC AOM
Wallonia Flanders Brussels Belgium Wallonia Flanders Brussels Belgium
No. of actively participating centres 24 48 13 85 6 3 3 12
No. of per protocol inclusions 353 329 78 760 27 8 4 39
Sex (% male) 55.2 46.4 50.7 50.9 44.4 75.0 50.0 51.3
Age in months (mean) 18.2 23.2 23.9 21.0 14.3 20.5 23.0 16.5
Age group 6–12 months (%) 22.7 0.0 0.0 10.5 40.7 0.0 0.0 28.2
12–24 months (%) 50.1 54.2 46.7 51.6 44.4 87.5 50.0 53.8
24–31 months (%) 27.2 45.8 53.3 37.9 14.8 12.5 50.0 17.9
Premature (%) 6.6 7.5 17.6 8.0 0.0 0.0 0.0 0.0
Breast-feeding (%) 32.8 25.7 40.0 30.4 11.1 37.5 25.0 17.9
At least one parent smokes (%) 27.8 17.0 21.3 22.4 37.0 62.5 0.0 38.5
Siblings at home (%) 1 46.2 42.3 45.2 44.4 40.7 25.0 25.0 35.9
2 20.6 16.1 19.2 18.5 51.9 62.5 75.0 56.4
No. of AOM episodes (%) 1 10.4 6.8 10.0 8.8 25.9 37.5 75.0 33.3
2 21.1 28.0 10.0 23.0 29.6 37.5 25.0 30.8
AB received in previous 3 months (%) 1 27.7 26.0 15.1 25.6 33.3 12.5 0.0 25.6
2 13.5 7.3 2.7 9.6 3.7 0.0 0.0 2.6
PCV13 doses received (%)a 1 1.4 1.5 1.3 1.5 0.0 0.0 0.0 0.0
2 98.0 89.7 96.0 94.2 96.2 87.5 100.0 94.7
Age-appropriate vaccinated (3 PCV-doses at age
14 months, %)
94.6 95.3 91.8 94.6 100.0 100.0 100.0 100.0
DCC = day-care centre, AOM = acute otitis media, No. = number, AB = antibiotics, PCV = pneumococcal conjugate vaccine.
a Vaccination status is based on vaccination documentation or parental reporting.
Table 2
Basic characteristics of infants in day-care by pneumococcal carrier status per method, Belgium, 2016.
Culture-based carriers (%) Denominatorsa P-value Chi2 LytA-based carriers (%) Denominatorsa P-value Chi2
Sex (male; female) 60.7; 60.9 387; 373 .970 80.9; 79.2 383; 370 .548
Premature (no; yes) 60.6; 63.3 686; 60 .682 80.1; 81.4 680; 59 .823
Breast-feeding (no; yes) 59.4; 63.5 527; 230 .290 79.9; 80.3 522; 228 .905
Siblings at home (no; yes) 56.8; 63.3 271; 460 .085 78.4; 81.1 269; 455 .386
At least one parent smokes
(no; yes)
63.1; 52.9 588; 170 .017 80.6; 78.6 583; 168 .558
History of AOM (no; yes) 62.9; 56.2 483; 258 .074 81.5; 77.2 480; 254 .167
AB treatment in last 3 months
(no; yes)
62.9; 57.8 453; 249 .186 84.6; 72.5 448; 247 <.001
Age-appropriate vaccinated
(no; yes)b
56.4; 60.7 39; 685 .591 76.3; 80.0 38; 680 .582
Sampling depth (<1/2; 1/2)c 59.9; 61.2 182; 554 .755 78.3; 80.3 180; 549 .563
Age group 6–12 months 58.8 80 .118 73.8 80 .234
12–24 months 64.3 392 81.9 392
24–31 months 56.6 288 79.4 281
a Missing values were due to incomplete questionnaires and/or LytA-result not available (n = 7).
b 3 PCV-doses at age 14 months.
c <1/2 = sample was taken at a depth of >1 cm from the nostril, but less than half the distance nostril-ear lobe, >1/2 = sample was taken at a depth of at least half the
distance nostril-ear lobe; AOM = acute otitis media, AB = antibiotics.
Table 3






Common cold Yes 9.2 2.0–16 <.001
No 4.4 2.6–6.2
PCV13 VT carriersb Yes 4.6 1.4–7.8 .560
No 5.8 3.3–8.3
AB treatment in last 3 months Yes 3.9 1.7–6.1 <.001
No 6.7 3.3–10
95%CI = 95% confidence interval, PCV13 VT = vaccine serotypes included in PCV13, AB = antibiotics.
a MWU-test = Mann-Whitney U Test.
b Assessed in culture-positive samples only.
18 I. Wouters et al. / Vaccine 36 (2018) 15–223.3.4. Antimicrobial susceptibility
Among the carried S. pneumoniae, culture-based resistance
against any of the five tested antibiotics was 42.4% in DCC and
48.1% in AOM infants. Antibiotic resistance against cotrimoxazole
was most frequent (32.7% in DCC; 40.7% in AOM), followed bytetracycline-resistance (16.9% in DCC; 3.7% in AOM). Sub-analysis
in DCC infants showed 12.1% multidrug-resistance (resistance ag
ainst  2 tested classes of antibiotics) and similar occurrence of
resistance in the two regions. In contrast, proportions of
erythromycin-resistant pneumococci were twice as high in the
Table 4
















PCV vaccinated population (2 vaccinations)a 346 (98.0) 295 (89.7) 72 (96.0) 713 (94.2) 26 (96.2) 7 (87.5) 4 (100.0) 37 (94.7)
Sp carriage (%) 205 (58.1) 207 (62.3) 50 (66.7) 462 (60.8) 19 (70.4) 5 (62.5) 3 (75.0) 27 (69.2)
PCV13 VT prevalence (%) All (incl. 3, 6A, 19A) 11 (5.4) 11 (5.3) 3 (6.0) 25 (5.4) 1 (5.3) 1 (20.0) 0 (0.0) 2 (7.7)
19F 4 (2.0) 6 (2.9) 3 (6.0) 13 (2.8) 0 (0.0) 1 (20.0) 0 (0.0) 1 (3.8)
14 4 (2.0) 0 (0.0) 0 (0.0) 4 (0.9) 1 (5.3) 0 (0.0) 0 (0.0) 1 (3.8)
23F 2 (1.0) 1 (0.5) 0 (0.0) 3 (0.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Non-PCV13 VT prevalence (%) 23B 37 (18.0) 24 (11.6) 3 (6.0) 64 (13.9) 2 (10.5) 1 (20.0) 0 (0.0) 3 (11.5)
23A 24 (11.7) 25 (12.1) 0 (0.0) 49 (10.6) 1 (5.3) 0 (0.0) 0 (0.0) 1 (3.8)
11A 15 (7.3) 18 (8.7) 7 (14.0) 40 (8.7) 4 (21.1) 0 (0.0) 0 (0.0) 4 (15.4)
PCV13 non-PCV10 VT prevalence (%) 3 0 (0.0) 1 (0.5) 0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
6A 0 (0.0) 1 (0.5) 0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
19A 1 (0.5) 1 (0.5) 0 (0.0) 2 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
DCC = day-care centre, AOM = acute otitis media, PCV = pneumococcal conjugate vaccine, Sp = S. pneumoniae, (non-) PCV13 VT = vaccine serotypes (not) included in PCV13,
PCV13 non-PCV10; VT = serotypes included in PCV13 but not in PCV10.
a Vaccination status is based on vaccination documentation or parental reporting.
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(Chi2, P = .001). Most prevalent erythromycin-resistant pneumo-
coccal serotypes in DCC infants were 15A (18.4%) and 33F
(16.3%) in Wallonia and 35B (20.8%) in Flanders (Fig. 2). For tetra-
cycline, occurrence of resistant pneumococci was similar in both
regions. Resistance to penicillin or levofloxacin was quasi inexis-
tent in DCC and in AOM.
4. Discussion
We report the overall pneumococcal carriage, the serotypes
involved and the antimicrobial susceptibility of the strains isolated
in infants in day-care and in infants with AOM in Belgium.
To our knowledge, this is the first study combining carriage
prevalence and carriage density results in two infant populations,
in a country where PCV13 is being replaced by PCV10 in the infant
vaccination programme.
NP carriage of S. pneumoniae in infants has been widely studied
after PCV7 implementation [36–39], however, only few studies
report on pneumococcal carriage after PCV13 was licensed:







Fig. 2. Most prevalent cotrimoxazole-resistant (left) and erythromycin-resistant (righ[29,40], households in the UK [30] and healthy infants in Italy and
in Norway [31,41]. None of these countries had a similar sequence
of vaccines as Belgium.
Culture-based carriage rates reported in infants in day-care vary
widely, from 8.3% in infants too young to have been vaccinated
[42] to 89.5% in PCV7 vaccinated infants between 6 and 34 months
of age [43]. In PCV vaccinated infants with AOM between 6 and 24
months of age, carriage rates between 11.8% [44] and 71.2% [32]
were reported. A Belgian study performed before PCV7 introduc-
tion, demonstrated a 21% carriage in DCC infants between 3 and
36 months [45]. Culture-based carriage in the current study
(60.8% in DCC infants and 69.2% in AOM infants) is at the higher-
end of the mentioned ranges. Even though there are methodologi-
cal differences, this finding suggests that carriage did not decrease
after PCV implementation. Studies comparing carriage pre- and
post-PCV indeed demonstrated no impact on overall pneumococcal
carriage [31,46]. This was also supported by the 80% LytA-based
carriage prevalence.
It is striking that, despite the high sample number and the high
detected carriage rates, no associations could be demonstrated
between carriage and demographic/clinical characteristics, except15A 33F 35B
Overall Wallonia Flanders
t) pneumococcal serotypes per region in Belgium, 2016 (error bars depict 95%CI).
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parental smoking (culture-based carriage). This is in contrast with
other carriage studies, reporting siblings [47], and/or recent antibi-
otic treatment [47,48], as significant carriage predictors among
culture-based studies. However, these studies did not exclude
infantswho received antibiotics in the seven days prior to sampling.
The unexpected negative association with parental smoking was
only found in the culture-based analysis, reducing its acceptability.
The low frequency of PCV13 vaccine serotypes (5.4% in DCC,
7.7% in AOM), is probably the result of the high PCV coverage in
Belgium (in 2015: 96.9% in Wallonia, in 2016: 94.9% in Flanders)
and the PCV13 programme having been in place for four years
[21,49]. The PCV13 serotypes most frequently identified were
19F (half of the cases) and 14. In DCC, serotypes 23F and 19A were
also identified. These findings corroborate reports from other
PCV13 using countries [31,41].
Among non-PCV13 serotypes, 23B (14.0% in DCC) and 11A
(15.4% in AOM) were most prevalent, as reported in other Euro-
pean studies [29,31,41].
However, since pre-PCV carriage data from Belgium are limited
to two studies with a different design (6–8 years before PCV13-
implementation in 1–30 day-care centres) [45,50], no conclusions
can be drawn on the impact of the previous years of PCV-use (up
to 2016) on pneumococcal carriage in Belgian infants.
Notwithstanding differences in the timing of the Walloon and
Flemish PCV immunisation programme switch, similar carriage
prevalence (general and PCV13 serotypes) was found in both
regions. Region-specific age criteria were applied in this first col-
lection season in order to obtain a homogenous baseline measure-
ment. However, if the different timing of the vaccine switch
induced temporal differences in serotype distribution between
the regions this will become clear in the next sampling periods.
Also, a possible increase in the carriage of serotypes 3, 6A and
19A might become apparent when the cohort of PCV10 vaccinated
infants grows over time.
The low frequency of antibiotic resistance among the carried
strains in this study is probably another positive consequence of
the low vaccine type carriage rate, since vaccine types that were
formerly common were often antibiotic-resistant. Indeed, for each
assessed antibiotic, resistance was at the lower edge of the range
reported in other carriage studies in unvaccinated infants in day-
care, which found resistance to penicillin, erythromycin and tetra-
cycline up to 71.4%, 90.5% and 48.5% respectively [45,51]. In addi-
tion, the regional difference in erythromycin resistance reflects the
regional difference in carriage of serotype 14, which is frequently
macrolide resistant.
Few studies [52,53] have measured the density of pneumococ-
cal carriage in infants, which is suggested to be a predictor of trans-
mission probability and possibly even disease. The wide variety in
absolute density we found (4.2  10–4.2  108 copies/mL in DCC, 3.
0  102–7.4  106 copies/mL in AOM), is higher than the range
mentioned in previous studies in a similar age group [53,54]. The
higher density in infants in day-care compared to infants with
AOM (of whom 12 of 32 carriers were not in day-care), would sug-
gest that residing in day-care predicts higher density. This hypoth-
esis will be tested when more data are available. In day-care
infants, common cold was related to higher pneumococcal loads,
as reported earlier [55]. This suggests interplay between viral
infections and pneumococcal colonisation. We also found lower
pneumococcal loads in infants treated with antibiotics more than
seven days prior to sampling, but overall similar loads for infants
carrying resistant and infants carrying susceptible strains, consis-
tent with the results of Hanke et al. [56]. The latter finding suggests
that antibiotic resistant strains circulating in healthy infants are as
viable and reproductive as non-resistant strains. Surprisingly, age
was not related to carriage density, but the narrow age rangeand the age distribution of the cohort studied might have limited
the detection of an age effect.
The high culture-based detection rate of S. pneumoniae indicates
that the established sampling protocol enables reasonably sensitive
monitoring of S. pneumoniae colonisation in infants over time. Nev-
ertheless, PCR screening of culture-negative samples was imple-
mented to further increase sensitivity. Planned analyses include
multiplex PCR andmicro-array to detectmultiple serotype carriage.
Another important strength of this study is the inclusion of both
DCC and AOM infants in one study which allows comparison of a
healthy and an ill population. This is informative, since differences
in carriage rate, serotype distribution and antimicrobial suscepti-
bility may occur. To improve the understanding of the relationship
between carriage and disease, serotype distribution in national IPD
surveillance data in infants under two years of age was also looked
at and compared in an exploratory analysis: serotype distribution
differed between IPD and carriers in DCC, because of differences
in invasiveness. However, the frequency of vaccine serotypes was
low in IPD and also in carriers in DCC. In 2016, serotypes most
often identified in IPD were 12F, 10A and 33F, with a combined
frequency of 29.5% (95%CI = 21.3–40.6%), but their combined
frequency among carriers in DCC was clearly lower (9.7%, 95%CI
= 7.3–12.9%). Furthermore, the combined frequency of the sero-
types 23B, 23A and 11A, which were most often identified among
carriers in DCC, was 33.1% (95%CI = 28.9–37.7%), which was higher
compared to the combined frequency of these serotypes in IPD
(6.5% 95%CI = 2.7–14.1%). The combined frequency of PCV13 vac-
cine serotypes was 12.9% (95%CI = 7.1–21.8%) in IPD and 5.4% (95
%CI = 3.6–8.0%) in carriers in DCC.
Regarding DCC, the randomised and population proportionate
recruitment strategy ensures representativeness for the Belgian
population. The number of AOM infants recruited in the first season
was low, but increasing recruitment in consecutive seasons will
allowmore sensitive comparisons between both infant populations.
Recruiting in similar seasons enhances comparability of yearly
sample collections, however, seasonality patterns cannot be
derived from our data.
We also included a sampling protocol quality check and foundno
indication that carriage or density were influenced by sampling
depth or an extra freeze-thaw cycle prior to culture. This suggests
that a representative NP sample can be taken at a depth between
1 cm from the nostril and half the distance between nostril and
ear lobe. Also, an extra freeze-thaw cycle prior to culturemay create
opportunities regarding the transport of NP samples. Nevertheless,
it might be that the sample size was too small to notice any
differences.5. Conclusion and perspectives
At baseline in 2016, culture-based carriage of PCV13 vaccine
serotypes was rare in infants in day-care and in infants with
AOM throughout Belgium and it was similar in the three Belgian
regions, as was the case for LytA-based pneumococcal carriage in
DCC infants, despite the use of different vaccines in 2016. Carriage
density (LytA-based) was related to antibiotic use and to clinical
signs of common cold.
The continued surveillance as currently planned will demon-
strate whether this situation will be maintained under the recent
PCV programme change.Acknowledgments
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